Analysts Anticipate Alphatec Holdings Inc (NASDAQ:ATEC) Will Announce Earnings of -$0.17 Per Share
Wall Street brokerages expect that Alphatec Holdings Inc (NASDAQ:ATEC) will post earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alphatec’s earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.12). Alphatec reported earnings per share of ($0.15) during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.3%. The company is expected to report its next quarterly earnings report on Thursday, March 5th.
On average, analysts expect that Alphatec will report full-year earnings of ($0.92) per share for the current financial year, with EPS estimates ranging from ($1.03) to ($0.80). For the next year, analysts expect that the firm will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.84) to ($0.24). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that cover Alphatec.
Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Wednesday, October 30th. The medical technology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). Alphatec had a negative return on equity of 151.54% and a negative net margin of 47.55%. The business had revenue of $29.20 million during the quarter, compared to analysts’ expectations of $26.85 million.
NASDAQ:ATEC traded down $0.14 during midday trading on Friday, reaching $7.29. 1,069,691 shares of the stock traded hands, compared to its average volume of 428,219. Alphatec has a 12-month low of $1.18 and a 12-month high of $7.93. The business has a 50-day moving average of $6.92 and a two-hundred day moving average of $5.86. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.67 and a current ratio of 3.72. The stock has a market capitalization of $397.01 million, a PE ratio of -12.53 and a beta of 1.56.
In other Alphatec news, Director Jeffrey P. Rydin sold 20,000 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $7.06, for a total value of $141,200.00. Following the completion of the transaction, the director now owns 243,746 shares of the company’s stock, valued at $1,720,846.76. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Craig E. Hunsaker sold 32,000 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $7.25, for a total transaction of $232,000.00. Following the completion of the transaction, the executive vice president now directly owns 797,448 shares of the company’s stock, valued at approximately $5,781,498. The disclosure for this sale can be found here. Insiders have sold 96,000 shares of company stock valued at $673,200 in the last three months. 34.32% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of Alphatec by 143.2% in the second quarter. Royal Bank of Canada now owns 6,686 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 3,937 shares during the period. Lindbrook Capital LLC grew its position in Alphatec by 40.0% during the third quarter. Lindbrook Capital LLC now owns 7,000 shares of the medical technology company’s stock valued at $35,000 after buying an additional 2,000 shares during the period. Advisor Group Inc. acquired a new stake in Alphatec during the second quarter valued at $36,000. JPMorgan Chase & Co. acquired a new stake in Alphatec during the second quarter valued at $36,000. Finally, Russell Investments Group Ltd. acquired a new stake in Alphatec during the second quarter valued at $40,000. Hedge funds and other institutional investors own 38.05% of the company’s stock.
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
See Also: Commodities
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.